Non small cell lung cancer
Conditions
Interventions
None listed
Sponsors
Kyoto Prefectural University of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients aged 20 years or older with PS0-2 at the time of consent (2) Patients with advanced or recurrent non-small cell lung cancer that is not curatively resectable (3) Patients with evaluable lesions by RECIST (version 1.1) (4) Patients who are scheduled to receive combination therapy with immune checkpoint inhibitors and chemotherapy (5) Patients whose tumor PD-L1 protein expression has been examined using formalin-fixed paraffin-embedded blocks in areas that do not interfere with pathological diagnosis, and whose consent has been obtained from the patient. (6) Patients who have been fully informed about the contents of this clinical study and have given free written consent from the research subject.
Exclusion criteria
Exclusion criteria: (1)Patients with a history of treatment with systemic chemotherapy or immune checkpoint inhibitors (However, molecularly targeted cancer drugs for patients with driver gene mutation positive, and postoperative adjuvant chemotherapy for patients with postoperative recurrence are acceptable) (2)Other patients who are deemed inappropriate by the physician in charge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, response rate, disease control rate, time to treatment failure, and incidence and grade of adverse events including immune-related adverse events Association of PD-L1 expression in tumors with response to combined chemoimmunotherapy Association between treatment response and patient background for combined chemoimmunotherapy | — |
Countries
Japan
Contacts
Public ContactYuki Katayama
Kyoto Prefectural University of Medicine Pulmonary Medicine
Outcome results
None listed